Organogenesis
ORGO Healthcare Drug Manufacturers Specialty & Generic
Organogenesis' revenue for fiscal 2025 (year ended December 2025) was $564.2 million, up 17.0% from fiscal 2024. In the quarter to June 2026, revenue fell 56.7%, EPS fell 670.0%, free cash flow grew 10.3% and total debt rose 10,940.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow ORGO
Organogenesis (ORGO) P/E ratio
Organogenesis has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 140× (March 2021) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 57.6× | — |
| FY2024 | 0.0× | — |
| FY2023 | 114× | 445.15% |
| FY2022 | 21.0× | 67.89% |
| FY2021 | 12.5× | (75.13%) |
| FY2020 | 50.2× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 57.6× | — |
| Sep 2025 | 0.0× | — |
| 28 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CPIX Cumberland Pharmaceuticals Inc. compare | n/m |
| DERM Journey Medical Corporation compare | n/m |
| CLVR Clever Leaves Holdings Inc. compare | n/m |
| ORGO Organogenesis | n/m |
| CRDL Cardiol Therapeutics Inc. compare | n/m |
| AKBA Akebia Therapeutics, Inc. compare | n/m |
| PROCF Sofgen Pharma S.A compare | 0.1× |
| OGI Organigram Global Inc. compare | 2.0× |
| BGM BGM Group Ltd. compare | 144× |
| Drug Manufacturers Specialty & Generic industry median | 19.2× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)